Although there are no drugs in clinical trials targeting ceramide signaling for glioblastomas, ASAH1 inhibitors (carmofur, N-oleoylethanolamine, and ARN14988) have been studied against multiple glioblastoma stem cell lines, U87, and patient-derived cell lines. This evidence concerns the gene ASAH1 and glioblastoma.